Ladarixin With Sotorasib in Advanced NSCLC
Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)
Sponsor: NYU Langone Health
This PHASE1 trial investigates Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation and is currently actively recruiting participants. NYU Langone Health leads this study, which shows 8 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Jan 2026 — Present [monthly]
Recruiting PHASE1
-
Mar 2025 — Jan 2026 [monthly]
Recruiting PHASE1
-
Sep 2024 — Mar 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Sep 2023 — Apr 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jul 2023 — Sep 2023 [monthly]
Not Yet Recruiting PHASE1
-
May 2023 — Jul 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- NYU Langone Health
For direct contact, visit the study record on ClinicalTrials.gov .